303-24: Ketamine vs ECT: Perspectives on Recent Comparative Effectiveness Trials

Product not yet rated

  • Register
    • Non-member - $22
    • Regular Member - $13
    • Retired Member - $13
    • Affiliate Member - $13
    • Student Member - $13

Internet Explorer does not cooperate well with this platform. Please see below for options that work with APNA eLearning Center programs.*

303-24: Ketamine vs ECT: Perspectives on Recent Comparative Effectiveness Trials

Compare the efficacy and tolerability of therapeutics strategies for treatment resistant depression including Ketamine versus ECT and medication augmentation versus switch, as well as how the research translates into clinical treatment.

  Sanjay J. Mathew, MD

Disclosures:  The APNA planners and faculty, with the exception of those listed below, have no relevant financial relationships to disclose. All relevant financial relationships listed for these individuals have been mitigated. Off-label uses will be discussed during this presentation.

Sanjay J. Mathew, M.D. is a consultant for Abbott, Clexio Biosciences, Douglas Pharmaceuticals, Engrail Therapeutics, Merck, Neumora, Relmada Therapeutics, Sunovion, and Xenon Pharmaceuticals. During the last 24 months, Dr. Mathew was a consultant and contracted researcher for Boehringer-Ingelheim and Engrail Therapeutics; and a consultant for Almatica, Biohaven, BioXcel, Brii Biosciences, Compass Pathways, Freedom Biosciences, Liva Nova, Perception Neurosciences, and Sage Therapeutics (these relevant financial relationships have ended).

Session Length:
  1 hour 15 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

  • Examine the efficacy and tolerability of therapeutic strategies for treatment resistance depression and how the research translates into practice.

Course Outcome:

  • 65% of learners will report an intent to make changes to their practice as a result of completing this course. 

Keywords:  Treatment-resistant Depression, Suicide, Depression, ECT, Antidepressants

Nursing Continuing Professional Development:
1.25 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Release date: July 8, 2024
Access to this course will end:
July 31, 2026

© 2024 APNA. Reproducing and distributing this material without the written permission of the American Psychiatric Nurses Association (APNA) is prohibited. 

*For an uninterrupted learning experience, please download and use Google ChromeMozilla FirefoxMicrosoft EdgeSafari, etc. If you continue to experience issues, you may need to update your browser.

Components visible upon registration.